Hepion Pharmaceuticals Completes 75 mg CRV431 Dosing, Initiates 225 mg Dosing in Phase 2a 'AMBITION' Clinical Trial for NASH

Stock Information for Hepion Pharmaceuticals Inc.

Loading

Please wait while we load your information from QuoteMedia.